What is Heparin Sodium Market?
The sodium salt of sulfated glycosaminoglycans is Heparin sodium and exist as a mixture of heterogeneous molecules different in molecular weights that retains a combination of activities against various factors of the blood clotting cascade. It is present in mammalian tissues & is typically obtained from the intestinal mucosa or other suitable tissues of domestic mammals used for food. It is an anticoagulant (blood thinner), prevents the formation of blood clots. It is used to treat as well as prevent blood clots in the veins, arteries, or lung, as well. Also, it is also before surgery to decrease the risk of blood clots. It comprised of polymers of alternating derivatives of α-D-glucosamido (O-sulfated, N-sulfated, or N-acetylated) & O-sulfated uronic acid (α-L-iduronic acid or β-D-glucuronic acid). Growing incidences of thrombosis is likely to impel the global Heparin sodium market growth during the forecasted period.
The market study is being classified by Type (Unfractionated Heparin, Low Molecular Weight Heparin, Modified Heparin and Heparinoids), by Application (Venous Thromboembolism, Complications of Pregnancy, Cardioversion of Atrial Fibrillation/Flutter and Others) and major geographies with country level break-up.
Pfizer Inc. (United States), Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (China), Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. (China), Bioiberica S.A.U. (Spain), OPOCRIN SPA (Italy), Yantai Dongcheng Pharmaceutical Group Co., Ltd. (China), Baxter International Inc. (United States), Aspen Holdings (The Netherlands), Sanofi-Aventis U.S. LLC (United States) and Sichuan Deebio Pharmaceutical Co., Ltd. (China) are some of the key players profiled in the study. Additionally, the Vendors which are also part of the research are Yantai Dongcheng Pharmaceutical Group Co., Ltd. (China), Changzhou Qianhong Bio-pharma Co., Ltd. (China) and Shenzhen Techdow Pharmaceutical Co., Ltd (China).
Research Analyst at AMA predicts that Chinese and United States Vendors will contribute to the maximum growth of Global Heparin Sodium market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Heparin Sodium market by Type, Application and Region.
On the basis of geography, the market of Heparin Sodium has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Growing incidences of thrombosis
- Increasing government funding to healthcare facilities improvement
- Increasing awareness about the availability of such treatment options among the patient population
- Strict government regulations
- Many cases of Adulterated Heparin
- Growing medical needs in emerging economies
"The United States Food and Drug Administration (FDA) is the regulatory body for heparin in United States and has been alerting healthcare providers of a change to the United States Pharmacopeia (USP) monograph for heparin, effective October 1, 2009. The United States Pharmacopeia (USP) has newly published updated compendial test methods for heparin sodium USP to contain the two screening tests previously posted on FDA’s website. Effective immediately, in accord with section 501(b) of the FD&C Act, all heparin sodium USP must meet compendial requirements as specified by the FDA."
Key Target AudienceHeparin Sodium manufacturers, Raw material suppliers, Pharmaceutical Industry, Industry associations and government organisations and Others